Identifying breast cancer patients at risk of relapse despite pathological complete response after neoadjuvant therapy.
Journal
NPJ breast cancer
ISSN: 2374-4677
Titre abrégé: NPJ Breast Cancer
Pays: United States
ID NLM: 101674891
Informations de publication
Date de publication:
07 Apr 2023
07 Apr 2023
Historique:
received:
09
11
2022
accepted:
13
03
2023
medline:
8
4
2023
entrez:
7
4
2023
pubmed:
8
4
2023
Statut:
epublish
Résumé
This retrospective pooled analysis aims to identify factors predicting relapse despite a pathologic complete response (pCR) in patients with breast cancer (BC). 2066 patients with a pCR from five neoadjuvant GBG/AGO-B trials fulfill the inclusion criteria of this analysis. Primary endpoint is disease-free survival (DFS); secondary endpoints is distant DFS (DDFS) and overall survival (OS). After a median follow-up of 57.6 months, DFS is significantly worse for patients with positive lymph nodes (cN+ vs cN0 hazard ratio [HR] 1.94, 95%CI 1.48-2.54; p < 0.001). In patients with triple-negative tumors, lobular histology (lobular vs other HR 3.55, 95%CI 1.53-8.23; p = 0.003), and clinical nodal involvement (cN+ vs cN0 HR 2.45, 95%CI 1.59-3.79; p < 0.001) predict a higher risk of DFS events. Patients with HER2-positive cT3/4 tumors have a significantly higher risk of relapse (cT3/4 vs cT1 HR 2.07, 95%CI 1.06-4.03; p = 0.033). Initial tumor load and histological type predict relapse in patients with a pCR.
Identifiants
pubmed: 37029138
doi: 10.1038/s41523-023-00525-2
pii: 10.1038/s41523-023-00525-2
pmc: PMC10082019
doi:
Types de publication
Journal Article
Langues
eng
Pagination
23Informations de copyright
© 2023. The Author(s).
Références
J Natl Cancer Inst. 2008 Apr 16;100(8):552-62
pubmed: 18398094
J Clin Oncol. 2007 May 20;25(15):2127-32
pubmed: 17513820
J Clin Oncol. 2008 Jan 10;26(2):246-52
pubmed: 18056680
Eur J Cancer. 2016 Jan;53:65-74
pubmed: 26693900
N Engl J Med. 2017 Nov 9;377(19):1836-1846
pubmed: 29117498
Lancet Oncol. 2007 Jan;8(1):55-62
pubmed: 17196511
N Engl J Med. 2019 Feb 14;380(7):617-628
pubmed: 30516102
Breast. 2015 Nov;24 Suppl 2:S26-35
pubmed: 26253814
N Engl J Med. 2017 Jun 1;376(22):2147-2159
pubmed: 28564564
Ann Oncol. 2013 Dec;24(12):2978-84
pubmed: 24136883
JAMA Oncol. 2016 Jun 1;2(6):751-60
pubmed: 26914222
Breast Care (Basel). 2011 Dec;6(6):419-426
pubmed: 22419894
Lancet Oncol. 2012 Feb;13(2):135-44
pubmed: 22257523
Ann Surg Treat Res. 2019 Apr;96(4):169-176
pubmed: 30941320
Ann Oncol. 2018 Dec 1;29(12):2341-2347
pubmed: 30335131
J Natl Cancer Inst. 2018 Jun 1;110(6):560-567
pubmed: 29659933
J Clin Oncol. 2011 May 20;29(15):1956-62
pubmed: 21482989
NPJ Breast Cancer. 2022 Mar 29;8(1):42
pubmed: 35351903
J Clin Oncol. 2010 Apr 20;28(12):2015-23
pubmed: 20308671
Lancet Oncol. 2018 Apr;19(4):497-509
pubmed: 29501363
J Clin Oncol. 2012 May 20;30(15):1796-804
pubmed: 22508812
J Clin Oncol. 2013 Oct 10;31(29):3623-30
pubmed: 24002511
Clin Cancer Res. 2017 Sep 15;23(18):5384-5393
pubmed: 28679772
J Clin Oncol. 2019 Sep 1;37(25):2226-2234
pubmed: 31082269
Lancet Oncol. 2018 Jan;19(1):27-39
pubmed: 29242041
Ann Surg. 2018 Oct;268(4):591-601
pubmed: 30048319
J Natl Cancer Inst. 2008 Apr 16;100(8):542-51
pubmed: 18398097
Lancet Oncol. 2014 Jun;15(7):747-56
pubmed: 24794243
N Engl J Med. 2012 Jan 26;366(4):299-309
pubmed: 22276820
Ann Oncol. 2014 Dec;25(12):2363-2372
pubmed: 25223482
Eur J Cancer. 2019 Sep;118:169-177
pubmed: 31377477
Genes Chromosomes Cancer. 2019 Mar;58(3):175-185
pubmed: 30520184
Eur J Cancer. 2013 Jul;49(10):2284-93
pubmed: 23541564
Mol Clin Oncol. 2015 Sep;3(5):1117-1122
pubmed: 26623062
Lancet. 2014 Jul 12;384(9938):164-72
pubmed: 24529560
Breast Cancer Res Treat. 2010 Nov;124(1):133-40
pubmed: 20697801
Breast Cancer Res Treat. 2017 May;163(1):83-91
pubmed: 28205044
Clin Cancer Res. 2013 May 15;19(10):2668-76
pubmed: 23575477
Ann Oncol. 2014 Jan;25(1):81-9
pubmed: 24273046